NO774315L - Fremgangsmaate ved fremstilling av antibiotiske formuleringer - Google Patents
Fremgangsmaate ved fremstilling av antibiotiske formuleringerInfo
- Publication number
- NO774315L NO774315L NO774315A NO774315A NO774315L NO 774315 L NO774315 L NO 774315L NO 774315 A NO774315 A NO 774315A NO 774315 A NO774315 A NO 774315A NO 774315 L NO774315 L NO 774315L
- Authority
- NO
- Norway
- Prior art keywords
- antibiotic
- lactam
- aminoglycoside
- lactam antibiotic
- penicillin
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title claims description 104
- 239000000203 mixture Substances 0.000 title claims description 63
- 238000000034 method Methods 0.000 title claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 28
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 23
- 229940126574 aminoglycoside antibiotic Drugs 0.000 claims description 21
- 229960000723 ampicillin Drugs 0.000 claims description 21
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 21
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 15
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 14
- 239000000787 lecithin Substances 0.000 claims description 14
- 229940067606 lecithin Drugs 0.000 claims description 14
- 235000010445 lecithin Nutrition 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 13
- 229930182566 Gentamicin Natural products 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 229960002518 gentamicin Drugs 0.000 claims description 13
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 8
- 239000013066 combination product Substances 0.000 claims description 8
- 229940127555 combination product Drugs 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 7
- 229940049954 penicillin Drugs 0.000 claims description 7
- 229960003669 carbenicillin Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229940126575 aminoglycoside Drugs 0.000 claims description 5
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims description 5
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 229960000603 cefalotin Drugs 0.000 claims description 4
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 229960000318 kanamycin Drugs 0.000 claims description 4
- 229930027917 kanamycin Natural products 0.000 claims description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 4
- 229930182823 kanamycin A Natural products 0.000 claims description 4
- 229940056360 penicillin g Drugs 0.000 claims description 4
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 229960000808 netilmicin Drugs 0.000 claims description 3
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 3
- 229930192786 Sisomicin Natural products 0.000 claims description 2
- 229960005456 sisomicin Drugs 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims 4
- 229940124587 cephalosporin Drugs 0.000 claims 4
- 150000001780 cephalosporins Chemical class 0.000 claims 4
- 235000005156 Brassica carinata Nutrition 0.000 claims 1
- 244000257790 Brassica carinata Species 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000000725 suspension Substances 0.000 description 19
- 238000002156 mixing Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 229940102213 injectable suspension Drugs 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229960004821 amikacin Drugs 0.000 description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 239000003708 ampul Substances 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 239000007785 strong electrolyte Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229950008560 almecillin Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 125000001271 cephalosporin group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QULKGELYPOJSLP-WCABBAIRSA-N penicillin O Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N21 QULKGELYPOJSLP-WCABBAIRSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 239000004297 potassium metabisulphite Substances 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75193776A | 1976-12-17 | 1976-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO774315L true NO774315L (no) | 1978-06-20 |
Family
ID=25024164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO774315A NO774315L (no) | 1976-12-17 | 1977-12-15 | Fremgangsmaate ved fremstilling av antibiotiske formuleringer |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS5379022A (fi) |
| AU (1) | AU3168077A (fi) |
| BE (1) | BE861876A (fi) |
| DE (1) | DE2756079A1 (fi) |
| DK (1) | DK561277A (fi) |
| FI (1) | FI773796A (fi) |
| FR (1) | FR2374031A1 (fi) |
| GB (1) | GB1540948A (fi) |
| GR (1) | GR70338B (fi) |
| IL (1) | IL53617A0 (fi) |
| IT (1) | IT1114939B (fi) |
| NL (1) | NL7713905A (fi) |
| NO (1) | NO774315L (fi) |
| PT (1) | PT67409B (fi) |
| SE (1) | SE7714312L (fi) |
| ZA (1) | ZA777493B (fi) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2964817D1 (en) * | 1978-09-06 | 1983-03-24 | Beecham Group Plc | Pharmaceutical compositions containing two beta-lactam derivatives |
| EP0012495B1 (en) * | 1978-12-08 | 1983-06-22 | Beecham Group Plc | Pharmaceutical composition comprising a water soluble salt of amoxycillin and polyvinylpyrrolidone, and a vial containing a unit dose of said composition |
| JPS5711909A (en) * | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
| EP0115001B1 (de) * | 1982-12-28 | 1988-06-15 | Bayer Ag | Stabile Aminoglykosid-Penicillin-Injektionsformulierungen |
| JPH0655676B2 (ja) * | 1984-07-26 | 1994-07-27 | ザ リポソ−ム カンパニ−、インコ−ポレ−テツド | 脂質小胞体中に含有された抗菌物質の混合物による抗菌活性の増高 |
| CN103349659A (zh) | 2006-09-26 | 2013-10-16 | 塔罗制药北美有限公司 | 液体药物组合物以及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT324281B (de) * | 1973-09-11 | 1975-08-25 | Spiegel Paul Dr Et Mr | Verfahren zur herstellung von gelatine-mikrokapseln mit flüssigem bzw. festem inhalt |
| FR2248024A1 (en) * | 1973-10-17 | 1975-05-16 | Aries Robert | Treatment of bovine mastitis using rifamycins - and pref. antibiotics active against gram negative bacteria |
| FR2272684A1 (en) * | 1975-01-07 | 1975-12-26 | Ito Shojiro | Antibiotic-unsaturated acid compsns. - having a synergistic effect against gram positive and negative bacteria |
| US3934013A (en) * | 1975-02-21 | 1976-01-20 | Syntex (U.S.A.) Inc. | Pharmaceutical composition |
| GB1532993A (en) * | 1975-03-07 | 1978-11-22 | Beecham Group Ltd | Injectable antibiotic compositions |
-
1977
- 1977-12-15 IL IL53617A patent/IL53617A0/xx unknown
- 1977-12-15 NL NL7713905A patent/NL7713905A/xx not_active Application Discontinuation
- 1977-12-15 ZA ZA00777493A patent/ZA777493B/xx unknown
- 1977-12-15 BE BE183475A patent/BE861876A/xx unknown
- 1977-12-15 GR GR54987A patent/GR70338B/el unknown
- 1977-12-15 PT PT67409A patent/PT67409B/pt unknown
- 1977-12-15 SE SE7714312A patent/SE7714312L/xx unknown
- 1977-12-15 FI FI773796A patent/FI773796A/fi not_active Application Discontinuation
- 1977-12-15 GB GB52268/77A patent/GB1540948A/en not_active Expired
- 1977-12-15 FR FR7737883A patent/FR2374031A1/fr not_active Withdrawn
- 1977-12-15 NO NO774315A patent/NO774315L/no unknown
- 1977-12-16 IT IT30798/77A patent/IT1114939B/it active
- 1977-12-16 AU AU31680/77A patent/AU3168077A/en active Pending
- 1977-12-16 DK DK561277A patent/DK561277A/da not_active Application Discontinuation
- 1977-12-16 DE DE19772756079 patent/DE2756079A1/de not_active Withdrawn
- 1977-12-16 JP JP15160477A patent/JPS5379022A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA777493B (en) | 1978-10-25 |
| IT1114939B (it) | 1986-02-03 |
| NL7713905A (nl) | 1978-06-20 |
| GR70338B (fi) | 1982-09-20 |
| AU3168077A (en) | 1979-06-21 |
| JPS5379022A (en) | 1978-07-13 |
| DE2756079A1 (de) | 1978-06-29 |
| SE7714312L (sv) | 1978-06-18 |
| BE861876A (fr) | 1978-06-15 |
| PT67409B (en) | 1979-05-22 |
| FR2374031A1 (fr) | 1978-07-13 |
| DK561277A (da) | 1978-06-18 |
| IL53617A0 (en) | 1978-03-10 |
| FI773796A (fi) | 1978-06-18 |
| PT67409A (en) | 1978-01-01 |
| GB1540948A (en) | 1979-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2062582B1 (en) | Antibiotic composition comprising beta-lactam antibiotics, aminoglycosides and buffers | |
| EP2062581B1 (en) | The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents | |
| EP1468697B1 (en) | Compositions containing piperacillin and tazobactam useful for injection | |
| RU2382647C2 (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| US4670262A (en) | Novel pharmacological compositions based on Cisplatinum and method for obtaining same | |
| IL99337A (en) | Injectable Florphenicol medicinal preparations | |
| JP2003519632A (ja) | 虚血状態下におけるアポトーシスを抑制する虚血治療剤 | |
| NO774315L (no) | Fremgangsmaate ved fremstilling av antibiotiske formuleringer | |
| CN101530393A (zh) | 一种克林霉素磷酸酯脂质体冻干制剂及其制备方法 | |
| EP0833640A1 (en) | Pharmaceutical composition containing lamotrigine | |
| KR20030044045A (ko) | 항생제 화합물의 제형화 방법 | |
| CN101003539A (zh) | 西林类化合物的氨丁三醇盐及其制备方法 | |
| US4698361A (en) | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same | |
| EP4192247A1 (en) | Antibacterial compositions and methods for fabricating thereof | |
| CN100516071C (zh) | 头孢类化合物的氨丁三醇盐及其制备方法 | |
| US3459854A (en) | Tetracycline cyclohexyl sulphamate and process for preparation | |
| US3737545A (en) | Alpha-aminobenzyl penicillins | |
| CN1281211C (zh) | 噁唑烷酮类物质在制备治疗哺乳动物眼部感染的药物中的用途 | |
| JP3242924B2 (ja) | 調製済みのアゾセミド（ａｚｏｓｅｍｉｄｅ）注射液 | |
| Axelrod et al. | Cephradine levels in human aqueous humor | |
| DE2910907C2 (de) | Antibakterielles Mittel | |
| WO2019126910A1 (zh) | 含有哌拉西林的组合物、其药物制剂及其应用 | |
| CN108047253A (zh) | 一种头孢曲松钠晶型化合物 | |
| EP1199077A1 (en) | Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers | |
| RU2038076C1 (ru) | Местно-анестезирующее средство для глаз |